BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » stem cell

Does Your Stem Cell Market Intelligence Utilize Futuristic Techniques?

December 4, 2017 By Cade Hildreth (CEO) Leave a Comment

DOES YOUR STEM CELL MARKET INTELLIGENCE PROVIDER USE FUTURISTIC TECHNIQUES?

2017 has never seen more opportunity for analysis of data, as the total global amount of data is now estimated to be 1.2 zettabytes.

Therefore, techniques for managing analysis of data must dynamically evolve.

While you may not understand the precise meaning of research terms such as meta-analysis, algorithmic analysis, or predictive trend analysis, it is important to ask yourself, are you embracing new and evolving methods for sourcing market data?

Futuristic (Definition): “Having or involving very modern technology or design”

Whether you are conducting your own market research or outsourcing it to a third-party, you should get clear answers to the following: [Read more…]

Filed Under: Stem Cells Tagged With: futuristic, market research, market research provider, market trends, stem cell, stem cell research

Stem Cell Product Launches, Acquisitions, Clinical Trials, and More

July 25, 2016 By Cade Hildreth (CEO) Leave a Comment

Stem Cell Product Launches, Acquisitions, Clinical Trials, and More

This week was a busy and active week within the stem cell industry, as evidenced by our coverage of stem cell markets below. I am excited to share with you.

Check it out and let me know what you think?


[Read more…]

Filed Under: Stem Cells Tagged With: cynata therapeutics, GE Healthcare, NiCord, regenerative medicine, stem cell, stem cell market

Cynata Prepares for Phase 1 Clinical Trial of iPSC-derived MSC Product CYP-001

June 21, 2016 By Cade Hildreth (CEO) Leave a Comment

Cynata Prepares for Phase 1 Clinical Trial of iPSC-derived MSC Product CYP-001 in July 2016

Cynata TherapeuticsAustralian stem cell company Cynata Therapeutics announced that it plans to file an application for regulatory approval within the UK to initiate a Phase 1 clinical trial of its iPSC-derived MSC product CYP-001 in July 2016.

This is a significant announcement, because it will be the world’s first allogeneic iPSC clinical trial.

Cynata’s Cymerus™ technology utilizes iPSCs originating from an adult donor as the starting material for generating mesenchymoangioblast (MCAs), and subsequently, for differentiating the cells into mesenchymal stem cells (MSCs). The outcome is that Cynata can  produce MSCs in unlimited quantities, in uniform batches, from a single donor, and at low cost. The company’s lead product produced using the s Cymerus™ technology is CYP-001.

This clinical trial will also be the first time that the company’s unique Cymerus technology is tested in humans.

[Read more…]

Filed Under: iPS Cells, MSCs, Stem Cells Tagged With: clinical trial, Cymerus, cynata therapeutics, regenerative medicine, stem cell

Cord Blood Stem Cells, as Compared to Other Stem Cell Alternatives

April 15, 2016 By Cade Hildreth (CEO) Leave a Comment

Cord Blood Stem Cells, as Compared to Other Stem Cell Alternatives - Depositphotos_26054387_m-2015.jpg

Since the first stem cell transplant occurred more than 50 years ago (1957), there has been a nearly exponential increase in stem cell transplants, and in late 2012, the millionth stem cell transplant occurred, a landmark event in stem cell medicine. Cord blood stem cells have distinct advantages over other sources, including that they are:

• Younger
• More adaptable
• More pure

These traits result from cord blood stem cells being the earliest (non-controversial) stem cells that can be extracted from a living human, and therefore haven’t been exposed to viruses, chemicals, or pollutants in the environment that can alter cell function.

While bone marrow stem cells are the most commonly recognized type of stem cell used in transplant, cord blood stem cells are increasingly showing advantages over other stem cell sources, including reduced immune reactions (such as GvHD) and a greater flexibility for HLA-mismatched cord blood units to be used in transplant. Although cord blood banks began offering their services in the United States in the mid-1990’s, it is within the past ten-years that the percentage of cord blood transplants has significantly increased.

Today, it is clear that the stem cells contained within cord blood banking have the potential to improve and save lives. Since the first cord blood transplant was performed in 1988, stem cells derived from umbilical blood have been used in more than 30,000 transplants worldwide. However, many expectant parents still do not fully understand the significance of cord blood storage.

Unfortunately, a study published in the 2006 Journal of Reproductive Medicine showed that a third of expectant parents are unaware of the option to preserve cord blood. Of the two-thirds who have some knowledge, 74% describe themselves as “minimally informed.” The study also identified that 84% of prenatal patients expected their obstetricians to be able to provide them with information on the subject of cord blood banking; however, only about 14% were educated about cord blood banking by their nurse or obstetrician.

Subsequently, a 2014 Parent Survey conducted by BioInformant Worldwide, LLC (600+ responses from recent and expectant parents), identified that these percentages have shifted very little since 2006, despite attempts in most countries worldwide to encourage healthcare providers to offer prenatal patients balanced information on public and private cord blood banking options.

To learn more about this market segment, view the and the “Complete 2015-16 U.S. Cord Blood Banking Industry Report.”


Want to be better informed than your competition? Get future stem cell industry updates.

 

About BioInformant

BioInformant is the first and only market research firm to specialize exclusively in the stem cell industry. BioInformant research has been cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, Medical Ethics, Xconomy, and Vogue Magazine. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry data.

Filed Under: Cord Blood, HSCs, Stem Cells Tagged With: blood bank, Complete 2015-16 U.S. Cord Blood Banking Industry Report, cord blood, stem cell

6 Reasons Your Survival Depends on Stem Cell Market Intelligence

April 13, 2016 By Cade Hildreth (CEO) Leave a Comment

Stem Cell Market Intelligence

The first and only market research firm to specialize in the stem cell industry, BioInformant has more than a decade of historical information on all segments of the stem cell market.

The following are six more reasons that your survival depends on stem cell market intelligence. [Read more…]

Filed Under: Stem Cells Tagged With: bioinformant, market intelligence, stem cell

  • 1
  • 2
  • Next Page »

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • U.S. Cord Blood Banking Survey Cord Blood Banking Survey of U.S. Parents [2017]
    Rated 0 out of 5
    $197
  • Exosome Companies 2020 Global Database of Exosome Companies
    Rated 0 out of 5
    $149 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.